(Date:10/13/2008)...wire/ -- The National Coalition for,Quality Colore...cerns over,the National CT Colonography Study publ...edicine. The evidence must be closely evaluated, a... is not without significant,potential risks. The N...y,remains the "Gold Standard" for colorectal cance...
(Date:10/13/2008)...-USNewswire/ -- The 2008 NCPA Digest,sponsored by...10th Annual,Convention. The Digest has been publis...st comprehensive portrait of the financial state o... calendar year. Last year,s,Digest provided an ins...,drug program had played a leading role in reducin...
(Date:10/13/2008)... after weekly doses up to 3 times recommended amou...-- Existing guidelines for treating vitamin D defi...w and put patients at high risk for bone loss and ...ohns Hopkins Children,s Center looked at 262 child...ldren were vitamin D-deficient, and most of them r...
(Date:10/13/2008)...bs.com and numerous newspaper affiliates have anno.... AtlantaJobs.com is the newest online job board ...kers in the metro Atlanta area. , ...AtlantaJobs.com and numerous newspaper affiliates...s.com is the newest online job board dedicated to...
Breaking Medicine News(10 mins):Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 2Health News:Positive Picture of Independent Community Pharmacies Emerges With Release of 2008 NCPA Digest, Sponsored by Cardinal Health 3Health News:Vitamin D Guidelines Too Low for Cystic Fibrosis Kids 2Health News:Atlanta Area Job Board Launches New Local Job Board to Connect Local Employers and Jobseekers 2(Date:10/8/2008)...tments for Spinal Cord, Other Nerve,Injuries -, P...rotein that enables,nerve cells to communicate wit...eveloping nervous system. Research into how that p...ve cells may provide a basis for eventual,treatmen...us system,including spinal cord injury., "This e...
(Date:10/8/2008)...ts Expand Testing Using Cellular ... Oct. 8 /- Wild Blueberry antioxidant...ts from a new study,showing Wild Blueberries outpe...e apples, bananas, red grapes and strawberries in ...tivity (CAA) assay. New research,published in the ...
(Date:10/8/2008)...-- Vical Incorporated (Nasdaq: VICL ),today is pr...l data,demonstrating that the company,s Vaxfectin(...protein-based infectious disease vaccines and,pept....D., Ph.D., Vical,s,Senior Vice President of Produ...sday, October 8, at the World Vaccine Congress (Ly...
(Date:10/7/2008)...-- McLaren Health Care and its Great,Lakes Cancer ...g medical,minds to share the latest work underway ...ncer treatments. The October 11th symposium, hoste...Sukamal Saha, M.D., an,award-winning surgical onco...orectal cancer has gained worldwide recognition an...
Breaking Medicine Technology:Protein Shown to Play a Key Role in Normal Development of Nervous System 2Protein Shown to Play a Key Role in Normal Development of Nervous System 3Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5News Media Advisory: World's Leading Surgical Oncologists to Gather at McLaren Regional Medical Center to Present Latest Work on Breast, Gastrointestinal Cancer Treatments 2Louis Drapeau Joins Bionovos Board of Directors 3974 1Louis Drapeau Joins Bionovos Board of Directors 3974 2Louis Drapeau Joins Bionovos Board of Directors 3974 3Isolagen Inc Promotes Todd Greenspan to Chief Financial Officer 28CFO 29 14386 1Isolagen Inc Promotes Todd Greenspan to Chief Financial Officer 28CFO 29 14386 2Isolagen Inc Promotes Todd Greenspan to Chief Financial Officer 28CFO 29 14386 3Isolagen Inc Promotes Todd Greenspan to Chief Financial Officer 28CFO 29 14386 4STERIS Corporation Names Michael J Tokich Chief Financial Officer 14384 1STERIS Corporation Names Michael J Tokich Chief Financial Officer 14384 2STERIS Corporation Names Michael J Tokich Chief Financial Officer 14384 3STERIS Corporation Names Michael J Tokich Chief Financial Officer 14384 4VaxGen Common Stock Now Quoted on OTC Bulletin Board 3971 1VaxGen Common Stock Now Quoted on OTC Bulletin Board 3971 2VaxGen Common Stock Now Quoted on OTC Bulletin Board 3971 3VaxGen Common Stock Now Quoted on OTC Bulletin Board 3971 4...f.--(BUSINESS WIRE)--Jul 6, 2007 - Cobalis Corp.,(...specializing in,anti-allergy medications, today re... III clinical trials for its drug,PreHistin(TM) in...nal allergic rhinitis, commonly known as hay fever...h placebo and,PreHistin-treated patient groups, th...
...pective biomarker trial in non-small cell lung can...tCall/ -- Response,Genetics, Inc. today announced ... the July 1 issue of the Journal of Clinical,Oncol...Excision-Repair Cross-Complementing 1 (ERCC-1) in ... cancer (NSCLC) predicts for,sensitivity to cispla...
Other Medicine Technology:Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 2Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 3Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 4Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 5Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4... surgical gloves were designed with the surgeon in... barrier protection, and value. It offers comfort ...e broader, anatomical design allows for an excelle...tivity and an effective grip, wet or dry. Beaded c...
The Next Generation in Operating Room Equipment and Management Solutions is here Today. NuBoom is a self-contained, pedestal-mounted boom that houses medical, audio and visual equipment.
...versatility and positioning, look to BERCHTOLD's O...design and 770 lb. weight capacity ensures configu... and patient sizes. The radiolucent phenolic table... accessed with a C-arm. An intuitive remote contro...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z37,158-0) or contact custom
Medicine Products: